TriangleOral MRT-2359 (NCT07745361)
Oral MRT-2359 trial for Castration-Resistant Prostate Cancer (CRPC) (NCT07745361). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for men over 18 with androgen-receptor-mutated, castration-resistant prostate adenocarcinoma after an androgen-receptor-pathway inhibitor. Small-cell disease is excluded. No more than one previous taxane regimen for resistant disease is allowed; androgen suppression continues.
The idea: oral MRT-2359 degrades GSPT1, disrupting protein production linked to MYC signaling. Oral apalutamide blocks androgen-receptor activation. Researchers test the combination’s PSA response, safety and drug levels. Screening includes a tumor biopsy. Prior androgen-receptor degraders or opevesostat exclude entry; additional prior-treatment rules apply.
This phase 2 study plans 25 patients. Monte Rosa sponsors five recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.